Cellular Immune Reactivity to Recombinant OspA and Flagellin from *Borrelia burgdorferi* in Patients with Lyme Borreliosis

Complexity of Humoral and Cellular Immune Responses

Andreas Krause,* Gerd R. Burmester,* Anne Rensing,* Christoph Schoemer,† Ulrich E. Schaible,‖ Markus M. Simon,‖ Peter Herzer,‖ Michael D. Kramer,‖ and Reinhard Wallich**

*Institute of Clinical Immunology and Rheumatology, Department of Medicine III. University of Erlangen-Nürnberg; †Institute of Clinical Microbiology, University of Erlangen-Nürnberg, W-8520 Erlangen, Germany; ‡Max-Planck-Institute for Immunobiology, W-7800 Freiburg, Germany; †Medizinische Poliklinik, W-8000 Munich, Germany; †Institute for Immunology, W-6900 Heidelberg, Germany; and **the German Cancer Research Center, W-6900 Heidelberg, Germany

Abstract

Patients with Lyme borreliosis (LB) usually develop a vigorous T cell response against the causative pathogen *Borrelia burgdorferi*, but little is known about the antigens recognized in the cellular response. Therefore, T cell reactivities against whole bacteria, recombinant 31-kD (outer surface protein A, OspA), and 41-kD proteins (flagellin) from *B. burgdorferi* were studied in patients with LB, non-LB patients, and healthy donors. In parallel, specific antibodies were determined by Western blot analysis. Virtually all patients with LB exhibited marked cellular responses to whole *B. burgdorferi*, which were significantly elevated compared with the control groups in both early and late disease stages. However, analyses using the purified antigens OspA and flagellin revealed considerable heterogeneity in the cellular reactivities among individuals as well as variations during the course of infection. T cell responses to OspA were significantly increased in patients with early LB compared with both control groups whereas in late-stage disease responses only exceeded those of non-LB patients and were not different from normal donors. Cellular immune reactivities to flagellin were significantly higher in early LB compared with both control groups. Reciprocally, several control subjects demonstrated marked cellular responses to OspA and flagellin, suggesting that reactions to these proteins may not always be related to LB. T cell reactivity did not correlate well with the presence of specific antibodies. Almost all seropositive patients in both early and late stage LB had serum antibodies against flagellin, but antibodies to OspA were detectable only in a subset of late LB sera. These data demonstrate the complexity of the humoral and the cellular immune responses to components of *B. burgdorferi*. (J. Clin. Invest. 1992. 90:1077-1084.) Key words: Lyme disease • T cell response • outer surface protein A • diagnosis • Western blot

Introduction

Lyme borreliosis (LB) is a multisystemic inflammatory disorder caused by the spirochete *Borrelia burgdorferi* (1-3). Previous studies have shown that most patients with LB develop an early and strong cellular immune reactivity to *B. burgdorferi*, which in early stages often precedes an only slowly evolving humoral response (4-7). Although the spectrum of specific antibodies against *B. burgdorferi* has been recognized in several studies (8-12), only little is known about the immunodominant T cell antigens. Two major proteins of *B. burgdorferi*, the outer surface protein A (OspA) and flagellin, appear to be of particular interest. The species-specific OspA is a 31-kD protein that is expressed in large amounts on the outer membrane of *B. burgdorferi*. OspA has been described to be antigenically variable between different isolates of *B. burgdorferi* (11, 13, 14). In mice experimentally inoculated with whole borreliae or with recombinant protein, OspA induces a vigorous humoral immune response (15, 16). In the severe combined immunodeficiency mouse model for LB (17), the manifestation of the disease could be prevented or mitigated by the application of anti-OspA antibodies when administered together with the causative agent (16, 18). Moreover, active immunization of immunocompetent mice with recombinant OspA induced the production of anti-OspA antibodies and protected from challenge with *B. burgdorferi*, making OspA a possible candidate for a vaccine (15, 16). However, in humans the humoral response to OspA as detected by immunoblotting is quite rare, and if present develops only at later stages (3, 5, 8, 9, 12). In contrast, antibodies to flagellin, a 41-kD protein associated with the flagella of *B. burgdorferi*, are detectable in nearly all patients with LB even in early stages of the disease (19, 20). However, flagellin from *B. burgdorferi* shows high protein sequence homologies with similar proteins from other spirochetes and bacteria not related to *B. burgdorferi*, which may lead to serological cross-reactivities (19, 21-24).

Recently, the genes for OspA (from the German isolate ZST) (25) and for flagellin (from the American isolate B31) (22) have been cloned by ourselves and by other groups (23, 26) and proteins have been produced in a recombinant, highly purified form (16, 22). Based upon our previous findings of high T cell responses towards whole *B. burgdorferi* bacteria...
(4), the objective of this investigation was to further define the differential cellular immune reactivities towards OspA and flagellin in patients with different clinical stages of LB. These findings were compared with the humoral responses as determined by immunofluorescence tests and Western blot analysis using the two domestic *B. burgdorferi* strains ZS7 and PKo 2-85.

The results obtained demonstrate that patients with early and late infections of LB show a significantly elevated cellular immune response to *B. burgdorferi*, which is in part directed against OspA and flagellin. Furthermore, the data provide evidence for a dissociation between the presence of *B. burgdorferi* specific antibodies and T cell reactivities in early and late stages of LB.

**Methods**

**Patients and control subjects.** In 36 patients with LB and 25 control subjects the cellular immune response to *B. burgdorferi* antigens was studied. The clinical characteristics of patients and controls are summarized in Table I. All individuals tested were newly entered into the study and therefore represent populations additional to the ones previously reported (4).

11 patients had early infections (disease stages 1 and 2 according to Steere (31)) at the time of study (group 1) with erythema migrans (*n* = 7), lymphadenitis cutis benigna (*n* = 2), meningopneumonitis (*n* = 1), and chorioiditis (*n* = 1). Of interest, the latter patient later developed severe arthritis and *B. burgdorferi* was cultured from synovectomy material. Six of the 11 patients had detectable antibodies against *B. burgdorferi* in an immunofluorescence assay (IFA) (4). The time elapsed between a recognized tick or insect bite and the examination of these patients ranged from 3 to 90 d.

The remaining 25 LB patients suffered from late stage disease (group 2) (3), including Lyme arthritis (*n* = 23) and localized scleroderma-like skin lesions (*n* = 2). 20 patients were seropositive and 5 were seronegative in the IFA. In the seropositive patients the diagnosis of late LB was based on a typical history of an erythema migrans in four patients, among these was one patient with a complete heart block. One additional seronegative patient had been seropositive before therapy with antibiotics but had converted to seronegative after therapy despite persistence of clinical symptoms. Of the seropositive patients seven had additional previous or concomitant symptoms of LB: two had a history of a recognized erythema migrans, one had acrodermatitis, and four had had typical meningopneumonitis with specific antibodies in the spinal fluid. In the sera of the remaining patients high IgG antibody titers (≥ 1:256 in IFA) against *B. burgdorferi* were detectable and in three individuals specific IgM antibodies were found. *B. burgdorferi* was cultured from a synovectomy specimen from one patient, and five individuals showed improvement after ceftriaxone therapy.

Most LB patients of both groups complained about additional constitutional symptoms of different intensities. 2 patients of group 1 and 13 patients of group 2, including the 5 seronegative individuals, had previously been treated with antibiotics, generally doxycycline or penicillin. However, in all patients symptoms of active LB were still present at the time of investigation, indicating active disease.

Two control groups were established. One group (group 3) consisted of 13 patients with different inflammatory disorders who had initially attended our clinic because of suspected LB but in whom LB was subsequently excluded. Of these, three had RA according to the American College of Rheumatology criteria (27), seven presented with HLA B27-associated reactive arthritis, two had inflammatory skin lesions (one lichen sclerosus et atrophicus, one allergic skin reaction) not related to borrelia infections, and one suffered from a neuritis nervi optici. In five patients (two seropositive RA, two classical Reiter's syndrome associated with chlamydial infections, one neuritis nervi optici), significant amounts of IgG antibodies against *B. burgdorferi* were determined, but there were no anamnestic or clinical criteria for active LB. Moreover, none of the patients had responded to recommended regimens of antibiotic treatment.

The second control group (group 4) included 12 healthy individuals. All healthy donors (HD) were negative for serum antibodies against *B. burgdorferi*. Members of our laboratories who work with *B. burgdorferi* were excluded from this group (28).

Expression and purification of recombinant *B. burgdorferi* proteins. *Escherichia coli* transformed by the bacterial expression vector pUEX1 and subsequently expressing OspA or 41-kD flagellin were grown overnight at 30°C in 10 ml Luria-Bertani broth with ampicillin (29). 1 ml of overnight cultures was expanded in 100 ml of medium and grown at 30°C with good aeration to a density of 8 × 10⁷ cells/ml (A₆₀₀ = 0.2). Expression of recombinant 41-kD flagellin was achieved by transferring the cells to 42°C for 2 h. After washing the cells in STE buffer (10 mM Tris, 100 mM NaCl, 1 mM EDTA, pH 8.0) the pellet was resuspended in 0.6 ml lysis buffer (25% sucrose/50 mM Tris pH 8.0). 150 µl of lysozyme (10 mg/ml) were added and the mixture was incubated for 15 min on ice followed by another 15 min incubation on ice with 18 µl DNaseI (10 mg/ml) and 5 µl 1 M MgCl₂. Finally, 250 µl of 4× detergent mix (1% Triton X-100, 0.5% Deoxycholate, 0.1 M NaCl, 10 mM Tris, pH 7.4) were added and incubated for 5 min on ice. After centrifugation, pellets were washed twice in buffer A (50 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 8.0), resuspended with 9 vol of buffer A containing 8 M urea and incubated for 1 h at room temperature. The samples were diluted with nine parts of buffer B (50 mM KH₂PO₄, 0.1 M NaPO₄, pH 10.7, 50 mM NaCl, 1 mM Tris) and stirred for 30 min at room temperature while keeping the pH at 10.7 by adding KOH. After adjusting the pH of the solution to 7.0 by the addition of HCI, the samples were dialyzed overnight in the cold against buffer A. Solutions were centrifuged for 10 min at 10,000 g (4°C), and the supernatants were further purified by antibody affinity chromatography. Recombinant OspA produced by *E. coli* cells was released into the culture supernatant and enriched by antibody affinity chromatography. Solutions

**Table I. Clinical Characteristics of Patients and Control Subjects**

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Sex (m/f)</th>
<th>Mean age (range)</th>
<th>Immunofluorescence assay % positive</th>
<th>Previous antibiotic therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with early Lyme borreliosis*</td>
<td>11</td>
<td>2/9</td>
<td>40 (25-75)</td>
<td>55</td>
<td>2</td>
</tr>
<tr>
<td>Patients with late Lyme borreliosis†</td>
<td>25</td>
<td>17/8</td>
<td>49 (15-78)</td>
<td>80</td>
<td>13</td>
</tr>
<tr>
<td>Non-Lyme borreliosis patients‡</td>
<td>13</td>
<td>7/6</td>
<td>40 (12-69)</td>
<td>38</td>
<td>5</td>
</tr>
<tr>
<td>Healthy donors</td>
<td>12</td>
<td>8/4</td>
<td>33 (23-76)</td>
<td>0</td>
<td>—</td>
</tr>
</tbody>
</table>

* Erythema migrans: *n* = 7; lymphadenitis cutis benigna: *n* = 2; meningopneumonitis: *n* = 1; chorioiditis: *n* = 1. † Arthritis: *n* = 23; localized scleroderma-like skin lesions: *n* = 2. ‡ Rheumatoid arthritis: *n* = 3; reactive arthritis: *n* = 7; inflammatory skin lesions: *n* = 2; neuritis nervi optici: *n* = 1.
containing recombinant *B. burgdorferi* proteins were centrifuged at 100,000 g for 1 h and passed over two columns in series at a flow rate of 20 ml/h: first, a mouse IgG-Sepharose column (2 ml at 5 mg/ml) to absorb some contaminants and to filter out any particulate material, and second, a LA-2 (for OspA) (23) or a LA-21 (for flagellin) (22) monoclonal antibody column (3 ml at 10 mg/ml). The column was washed with five volume columns of PBS and the bound material was then eluted using 0.1 M glycine/HCl, pH 3.0. Finally, the recombinant antigens purified by chromatography were dialyzed against PBS (16). Purity of antigens was tested by SDS-PAGE and silver staining, revealing only very faint containing bands. Moreover, cellular immune responses were studied initially using whole urea lysates of transformed *E. coli* and demonstrated only minor T cell reactivities that were not different between normal donors and patients.

**Lymphocyte proliferation assay.** The lymphocyte proliferation assay was performed as described previously (4). PBMCs were isolated from heparinized peripheral venous blood by standard centrifugation on a Ficoll-Hypaque (Nycomed Pharma, Oslo, Norway) gradient. They were resuspended in RPMI 1640 medium (Biochrom KG, Berlin, Germany) supplemented with L-Glutamine (2 mM, Sigma Chemical Co., St. Louis, MO), Heps buffer (15 mM, Gibco Laboratories, Eggenstein, Germany), penicillin/streptomycin (100 IU/ml and 100 μg/ml, respectively; Gibco Laboratories), and 10% autologous serum and cultured in triplicate at a concentration of 1 × 10⁶ cells/well in round-bottom microtiter plates (Nunc, Roskilde, Denmark). Cells were stimulated with whole *B. burgdorferi* (German isolate PKo 2-85, kindly provided by Dr. Vera Preac-Mursic, Max-von-Pettenkofer-Institute, Munich, Germany) (30) at concentrations of 1 × 10⁵ and 1 × 10⁶ bacteria/well (corresponding to 0.3 and 3 μg protein/well, respectively) or with recombinant 31- and 41-kD proteins at final concentrations of 10, 0.1, and 0.01 μg/ml. In previous experiments the T cell nature of the cellular response to *B. burgdorferi* antigens had already been demonstrated since only purified T cells but not the non-T cell fraction proliferated in response to stimulation with *B. burgdorferi* (4). Control cultures received medium alone or ultrasonicated *Treponema phagedenis* (Behringwerke, Marburg, Germany) at 7 and 0.7 μg/well. The latter spirochete is of the same family as *B. burgdorferi*, and was used as a control antigen. All antigen concentrations had been tested in dose-response experiments and had been found to induce optimal and maximum stimulations in either of the concentrations mentioned above. Therefore, various concentrations were used throughout the experiments. Cultures were incubated at 37°C in a humidified atmosphere with 5% CO₂ for 6 d. Subsequently, 1 μCi of [³H]thymidine (sp act 2 Ci/mmol; Amersham Buchler, Braunschweig, Germany) was added to each well for 18 h. Cells were harvested semiautomatically and tritiated thymidine incorporation was determined in a liquid scintillation counter (LKB Wallac, Turku, Finland). Results were expressed as average disintegration per minute (dpm) quench correction by an internal standard) of triplicate wells. Δdpm was calculated by subtracting the control values with medium alone from the dpm obtained in the presence of antigen. In all experiments, for each of the stimuli, i.e., whole borreliae, sonicated *T. phagedenis*, and recombinant proteins, only the maximum values of all concentrations tested were shown.

**Western blot analysis.** Sera from all 36 patients with LB (groups 1 and 2) and from 12 non-LB patients (group 3) were obtained on the same day as the PBMCs and were subjected to immunoblot analysis for specific antibodies against *B. burgdorferi*. Since there may be antigenic heterogeneity between *borrelia* strains, resulting in different results in the immunoblots (11, 12, 31), two different german *B. burgdorferi* isolates PKo (30) and ZST (17) (from which the gene for the recombinant OspA had been cloned) were used as antigens. In brief, whole borreliae were lysed in Triton/glycerin/SDS buffer, the protein concentration was determined, and then 5 μg protein/lane were separated by SDS-PAGE with 10 or 12% polyacrylamide running gels as described by Langen (32). Proteins were transferred to nitrocellulose and, after blocking with 0.1% bovine serum albumin or with 3% gelatin, incubated with the sera at a 1:100 dilution. Bound immunoglobulins were visualized with appropriate peroxidase-conjugated goat anti-human immunoglobulin antibodies. Based upon own observations with patient and control sera (unpublished data) and according to the suggestions of Zöller et al. (12) as well as Grodzicki and Steere (9), blots fulfilling one of the following criteria were considered positive: (a) in early disease stages a clear 41-kD band and at least two additional bands with one band corresponding to the 21-, 30-, 60-, or 87-kD protein; (b) in late LB five or more antibodies against *B. burgdorferi* proteins with a strong 18-, 21-, 23-, 30-, 41-, 75-, or 87-kD band. For further evaluation, special attention was placed on the presence of antibodies against OspA and flagellin.

**Immunofluorescence assay.** The IFA was performed as described previously (4). All sera were preabsorbed with *T. phagedenis* before testing in order to eliminate cross-reacting antibodies. After this procedure, the IFA was highly specific for *B. burgdorferi*, and there virtually was no cross-reaction to other spirochetes, especially *Treponema pallidum*. In a random Bavarian (Franconian) population (*n = 334*) matched for similar living areas as the patient population, 276 (83%) sera were seronegative, 33 (10%) had titers of 1:16, 6 (2%) of 1:32, 10 (3%) of 1:64, and 9 (3%) of ≥1:128. Therefore, in the clinical situation, titers from 1:64 on were regarded as indicative of a definite serological reaction (10). For the detection of specific IgM antibodies, sera were additionally pretreated with rheumatoid factor absorbent (Behringwerke) to prevent false-positive results due to rheumatoid factor absorbent or false-negative results because of competitive inhibition by specific IgG.

**Statistical analysis.** Data are presented as median values (range) unless otherwise indicated. The proliferation values of the four groups tested were compared by the Mann-Whitney *U* test, and *P* values of < 0.05 were considered to be significant. Correlations between response values to different antigens within the study groups were determined by the Spearman rank correlation test. Correlation coefficients were considered significant at *P* < 0.01.

**Results**

*T* cell response towards whole *B. burgdorferi* and *T. phagedenis*. The cellular immune responses to in vitro stimulation with whole *B. burgdorferi* bacteria were significantly elevated in patients with early (median 37,700 dpn) and with late LB (median 40,000 dpn) as compared with non-LB patients (median 13,200 dpn, *P < 0.0005*) or HD (median 18,000 dpn, *P < 0.002*) (Fig. 1A; Table II). This increased lymphoproliferative response did not correlate with the presence of specific antibodies against *B. burgdorferi* and was already detectable as early as 2 d after the onset of the erythema migrans. No significant differences in proliferation values were observed either between patients with early and late infections or between non-LB patients and HD. Despite highly significant differences in response rates between LB patients and control subjects, the majority of control individuals showed responses to whole *B. burgdorferi*, which, however, generally were marginal in magnitude (Fig. 1A).

In contrast to *B. burgdorferi*, stimulation of PBMC with *T. phagedenis* generally resulted in moderate proliferative responses in all four groups tested. Only in patients with LB and irrespective of the disease stage did *T* cell proliferation induced by *B. burgdorferi* always exceed responses elicited by stimulation with *T. phagedenis* (early: median values 37,700 vs. 7,800 dpn, *P < 0.004*, late: 40,000 vs. 9,400 dpn, *P < 0.0001*) (Fig. 1A, A and B; Table II).

**T cell responses to recombinant OspA and flagellin.** Fig. 1C demonstrates that the cellular immune responses to OspA were significantly increased in patients with early LB (median
16,000 dpm) compared with non-LB patients (median 4,400 dpm, \( P < 0.002 \)) and HD (median 5,000 dpm, \( P < 0.02 \)) (Fig. 1 C; Table II). There were only two patients with very low response values of 1,900 and 3,000 dpm, whereas the majority of patients showed marked responses of \( > 10,000 \) dpm. In patients with late infection, the proliferation values (median 13,500 dpm) were significantly higher compared with non-LB patients (\( P < 0.02 \)) but did not significantly exceed the responses obtained in HD (group 4) (\( P = 0.11 \)). Seven patients of group 2 exhibited only weak responses of \( < 5,000 \) dpm, and 16 individuals responded well with \( > 10,000 \) dpm. Of special interest, one patient in the non-LB group and four HD (all five of them seronegative) showed marked T cell reactivities to OspA exceeding the median value of late LB patients.

In contrast, T cell responses to flagellin (Fig. 1 D) were significantly elevated only in patients with early LB (median 22,700 dpm) and exceeded the proliferation values of the two control groups (group 3: median 8,000 dpm, \( P < 0.008 \); group 4: median 11,300 dpm, \( P < 0.05 \)). Responses of late LB patients (median 12,300) did not significantly differ from those of patients with early LB or of the control groups (Table II). Only two patients with early LB, eight individuals with late infection, six non-LB patients, and three HD showed low responses of \( \leq 5,000 \) dpm, whereas the majority of individuals tested responded well (\( > 10,000 \) dpm) to flagellin. One individual with early and six individuals with late infections did not significantly respond to either OspA or flagellin; however, five of these seven patients elicited marked proliferative reactions.
to stimulation with whole *B. burgdorferi*. In the control groups, T cells derived from 4 of 13 non-LB patients and 6 of 12 HD showed response values to flagellin above the median value of late LB patients (Fig. 1 D; Table II).

Table III shows that in patients with LB there were strong, consistent, and significant correlations between T cell responses to the spirochetal antigens tested. In contrast, in healthy donors and non-LB patients generally no consistent correlations were observed. Here, only responses to *B. burgdorferi* and *T. phagedenis* correlated significantly (*r* = 0.70, *P* < 0.01) in non-LB patients, whereas in HD a very strong and highly significant correlation was observed between proliferation values after stimulation with *T. phagedenis* and OspA (*r* = 0.91, *P* < 0.001).

**Humoral immune responses to *B. burgdorferi* proteins.** Of the six patients with early LB who were seropositive in the IFA, three showed a restricted antibody pattern with bands corresponding to the 41-kD protein and one or two additional bands, whereas the remaining three showed an extended pattern of more than five antigens recognized (Fig. 2). Two of five individuals with negative IFA immunoblots were considered positive according to the criteria mentioned in Methods. These sera had also been analyzed without preabsorption, again yielding negative results in the IFA. Antibodies against the 31-kD protein were not detectable and there were no major differences between blots using strains PKo or Z57.

In the group of patients with late LB (group 2), all of the 20 IFA-positive patients also had positive immunoblots revealing at least 5, and in some cases > 10, intense bands. All but 3 seropositive patients exhibited antiflagellin antibodies, and 16 individuals showed antibodies against a 87-kD protein. Antibodies against OspA of PKo were found in only four patients; antibodies against OspA of Z57 were found in only three individuals. In these patients, T cell proliferation values to OspA were 24,300, 14,600, 12,400 dpm, and, interestingly, in one patient T cells did not react to OspA at all. It is noteworthy that in most individuals antibodies against a 30-kD protein were observed as has been described by others (12). This protein could be clearly distinguished from OspA with sera-containing antibodies against both proteins and by additional experiments using monoclonal antibodies. Moreover, on most blots OspA could easily be recognized by a light, “negatively stained” band with missing background staining activity of the nitrocellulose strip due to the presence of high amounts of this protein (Fig. 2).

In group 3 (non-LB patients), positive immunoblots were observed in all five seropositive patients. These blots generally showed bands corresponding to flagellin and four or more additional bands. As in early LB, antibodies against OspA were not detectable. In the majority of the seronegative patients with LB, non-LB patients and HD weak 41-kD bands and sometimes faint additional bands were observed (Fig. 2).

**Complexity of humoral and cellular responses.** In Table IV, results of lymphocyte proliferation assays and serological analyses of individual patients are outlined, demonstrating the complexity of cellular and humoral responses against components of *B. burgdorferi*. In the early LB group (group 1), i.e., patients 2, 3, and 4 exhibited high T cell reactivities but differed remarkably in antibody responses. In contrast, patient 1 showed a weak cellular response in spite of a high antibody titer. In patients with late infections (group 2), almost all combinations of high and low responses could be observed and no consistent correlations between T cell reactivities to *B. burgdorferi* proteins or between humoral and cellular responses were detectable. Obviously, the cellular immune response to *B. burgdorferi* proteins as assessed by lymphoproliferative assays was very complex.

### Table II. Statistical Analysis of Differences of Proliferative Values of PBMC* between the Four Groups Studied (Mann-Whitney U Test)

<table>
<thead>
<tr>
<th>Comparison of groups</th>
<th>Responses to</th>
<th>B. burgdorferi</th>
<th>T. phagedenis</th>
<th>OspA</th>
<th>Flagellin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early LB vs. late LB$^1$</td>
<td>NS$^9$</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Early LB vs. non-LB</td>
<td>0.0005$^{10}$</td>
<td>NS</td>
<td>0.002</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>Early LB vs. HD</td>
<td>0.002</td>
<td>NS</td>
<td>0.02</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>Late LB vs. non-LB</td>
<td>0.0001</td>
<td>NS</td>
<td>0.02</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Late LB vs. HD</td>
<td>0.0001</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Non-LB vs. HD</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

* Proliferative responses of PBMC were determined by a lymphocyte proliferation assay (for methods see Fig. 1). $^1$ Early LB (group 1): patients with early Lyme borreliosis, late LB (group 2): patients with late Lyme borreliosis, non-LB (group 3): patients with inflammatory disorders not related to Lyme borreliosis, HD (group 4): healthy donors. For further definition of groups 1 to 4, see Table I. $^9$ NS, not significant (P > 0.05). $^{10}$ P values.

### Table III. Correlation Analysis (Spearmann Rank Correlation) of Proliferative Responses of PBMC to *B. burgdorferi*, *T. phagedenis*, and to Recombinant OspA and Flagellin from *B. burgdorferi* within the Four Groups Tested

<table>
<thead>
<tr>
<th>Comparison of responses to</th>
<th>Groups</th>
<th>Early LB$^*$</th>
<th>Late LB</th>
<th>Non-LB</th>
<th>HD</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>B. burgdorferi</em> vs. <em>T. phagedenis</em></td>
<td>0.7497$^7$</td>
<td>0.7258$^8$</td>
<td>0.7042$^3$</td>
<td>0.4561</td>
<td></td>
</tr>
<tr>
<td><em>B. burgdorferi</em> vs. OspA</td>
<td>0.6155</td>
<td>0.4834$^4$</td>
<td>0.5882</td>
<td>0.5028</td>
<td></td>
</tr>
<tr>
<td><em>B. burgdorferi</em> vs. flagellin</td>
<td>0.7251$^4$</td>
<td>0.7205$^5$</td>
<td>0.3571</td>
<td>0.4976</td>
<td></td>
</tr>
<tr>
<td><em>T. phagedenis</em> vs. OspA</td>
<td>0.8375$^6$</td>
<td>0.8033$^3$</td>
<td>0.6273</td>
<td>0.9088$^9$</td>
<td></td>
</tr>
<tr>
<td><em>T. phagedenis</em> vs. flagellin</td>
<td>0.9031$^1$</td>
<td>0.7996$^4$</td>
<td>0.2172</td>
<td>0.3314</td>
<td></td>
</tr>
<tr>
<td>OspA vs. flagellin</td>
<td>0.7121$^3$</td>
<td>0.7296$^6$</td>
<td>0.0396</td>
<td>0.2871</td>
<td></td>
</tr>
</tbody>
</table>

* For definition of groups 1 to 4 see Tables I and II. $^4$ Correlation coefficient. Significant correlations are written in bold numbers and are indicated by $^7$ (P < 0.01) and $^8$ (P < 0.001).
majors proteins of *B. burgdorferi*, OspA and flagellin, in patients with LB:

(a) Patients with LB showed a significantly elevated T cell response to whole *B. burgdorferi* bacteria compared with non-LB patients and normal controls. This elevated response was already detectable in early disease stages and did not correlate with the presence of antibodies against *B. burgdorferi* in these patients.

(b) The *B. burgdorferi*-specific T cell responses observed included those directed against the 31-kD (OspA) and the 41-kD (flagellin) proteins of *B. burgdorferi*. However, there was a considerable variation of proliferation values ranging from a lack of T cell proliferation to very high response values. In early infection, cellular responses to both OspA and flagellin significantly exceeded those of both control groups whereas in late infection only responses to OspA were significantly elevated when compared with the non-LB group. In contrast to the control groups, in patients with LB response values to the spirochetal antigens generally showed high correlations.

(c) Irrespective of the disease stage, in vitro T cell responses to either whole *B. burgdorferi* or to the recombinant proteins did not correlate with the presence of specific antibodies in the patient sera.

Our data corroborate the results of previous studies by Dattwyler et al. (5) and by our group (4), revealing that most patients with LB develop an early and vigorous cellular immune response to the causative agent *B. burgdorferi* that does not correlate with the presence of specific antibodies. However, all previous tests used whole or sonicated bacteria; therefore, only little was known about the T cell responses against individual *B. burgdorferi* antigens. Recently, two major proteins of *B. burgdorferi*, i.e., OspA and flagellin, had been produced in a recombinant form by our group (22, 24) and were used for T cell stimulation assays in this study. The data obtained demonstrate that both antigens are already able to induce strong cellular immune reactions in vitro in early stages of the infection; only 1 of 11 patients with early LB did not markedly respond to either protein. However, in both groups of LB patients, T cell proliferative responses were quite variable and ranged from no or marginal to very high responses. Even in late stage disease a considerable number of patients only exhibited weak responses. Though quantitative differences in cellular reactivities may to some extent be due to different compartmentalization of the immune response, these data may indicate a restricted clonal T cell expansion in infected individuals with differential reactivities to various *B. burgdorferi* antigens. This selective expansion of responding cells may depend on the HLA profile. In this respect, recent findings by Steere et al. (33) are of special interest. These authors documented a high association of chronic LB with certain HLA-DR2 and -DR4 alleles. To address these questions, HLA typing of our study population and analysis of specific T cell clones are underway in our laboratory.

A particularly interesting finding in the present and in earlier (5) investigations is the complexity of the humoral and the cellular immune responses. Great care was taken to rule out technical problems as a reason for the inability to detect specific antibodies. Both immunofluorescence and Western blot analyses were performed in all individuals tested. Moreover, immunoblots were carried out in two separate laboratories with two different isolates of *B. burgdorferi*. The presence of immunoreactive bacterial proteins was verified using monoclo-

**Figure 2.** Western blot analysis of antibodies to *B. burgdorferi* proteins in sera from (A) HD (lanes 1–3), (B) patients with early LB (lanes 4–6), and (C) patients with late LB (lanes 7–9). *B. burgdorferi* bacteria were lysed, and 5 μg protein per lane were separated by SDS-PAGE with 10% running gels. Proteins were transferred to nitrocellulose and probed with the sera at 1:100 dilutions. Bound immunoglobulins were detected by peroxidase-conjugated goat anti-human antibodies. Molecular weight markers are shown on the right.

feri did not depend on the IFA titer or on the presence of specific IgM antibodies. As could be observed in the early LB group, patients with almost similar T cell reactivities against whole *B. burgdorferi* bacteria (patients 8–13) showed marked differences in both cellular and humoral responses against *B. burgdorferi* antigens. Patients 12 and 14 exhibited the highest cellular reactivities against OspA but had negative IFAs and, in the immunoblot, antibodies against this protein were not found. Conversely, T cells of one of the patients with anti-OspA antibodies (patient 10) did not respond to stimulation with OspA. In the sera of patients 11, 13, and 16, antibodies against flagellin were not detectable but all three patients showed marked cellular reactions to the 41-kD antigen. However, some patients with strong anti-41-kD bands in Western blot analysis only showed weak or even no cellular reactivities to flagellin (patients 5, 8, and 9). The three non-LB patients with the highest IFA titers (patients 17–19) only demonstrated weak T cell responses against *B. burgdorferi*. Interestingly, the patient with RA showed almost no cellular antigen response as has been observed in earlier studies (4). In contrast, the patient with the highest cellular response in this group was seronegative in both IFA and Western blot.

**Discussion**

The following principle points emerged from this investigation of the cellular immune responses to two of the recombinant
Table IV. Complexity of Cellular and Humoral Immune Responses to B. burgdorferi, OspA, and Flagellin

<table>
<thead>
<tr>
<th>No.</th>
<th>Initials</th>
<th>Age, sex</th>
<th>Diagnosis</th>
<th>B. burgdorferi</th>
<th>OspA</th>
<th>Flagellin</th>
<th>T. phagedenis</th>
<th>IFA-Titer (IgG, IgM)</th>
<th>Immunoblot</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>dpm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>kD</td>
</tr>
</tbody>
</table>

A. Patients with early Lyme borreliosis (group 1)

1. E.H. 75, f  LACB§  8,500 9,500 2,000 3,500 1:256, neg.  87, 82, 46, 41, 40, 39, 29
2. W.L. 47, f  Choroiditis  56,500 34,000 23,000 26,000 1:128, neg.  75, 58, 41, 40, 30, 14
3. A.M. 28, f  EM§  79,000 30,500 76,500 45,500 neg., neg.  neg.
4. M.P. 25, m  EM  85,000 25,000 34,500 18,500 1:32, 1:16  41, 23, 20

B. Patients with late Lyme borreliosis (group 2)

5. O.P. 52, m  Arthritis  12,000 0 3,000 0 1:32, neg.  87, 58, 56, 41, 40, 30
6. H.M. 58, f  SLSL§  21,500 14,500 12,500 9,500 1:256, neg.  87, 82, 66, 60, 58, 56, 55, 47, 44, 41, 40, 37, 31, 30
7. F.D. 60, m  Arthritis  24,000 24,000 10,000 0 1:64, 1:16  87, 58, 56, 47, 41, 39, 34, 31, 30, 29, 24, 22
8. J.F. 51, m  Arthritis  40,000 12,000 5,500 17,000 1:64, neg.  87, 75, 58, 56, 55, 47, 41, 40, 23, 18
9. C.H. 15, f  Arthritis  40,000 0 0 0 1:64, 1:32  75, 56, 41, 30, 23
10. E.T. 50, f  SLSL  40,500 0 26,500 0 1:64, 1:16  60, 44, 41, 31, 23
11. H.G. 53, m  Arthritis  41,000 21,000 14,000 10,000 1:512, neg.  87, 75, 56, 55, 44
12. J.B. 50, m  Arthritis  47,000 54,500 24,000 31,000 neg., neg.  neg.
13. G.S. 56, m  Arthritis  47,500 18,000 19,000 11,000 1:256, neg.  87, 66, 58, 56, 55, 30, 23, 18, 16
14. K.E. 38, f  Arthritis  50,000 48,000 42,500 32,500 neg., neg.  (87, 82, 75, 58, 55, 44, 41, 39) weak bands
15. H.B. 78, m  Arthritis  56,000 12,500 18,500 2,500 1:128, neg.  87, 82, 75, 56, 41, 40, 37, 31, 30, 29, 23, 21, 18, 16
16. E.B. 56, m  Arthritis  104,000 32,500 36,500 40,000 1:64, neg.  87, 82, 75, 58, 56, 30, 21

C. Non-LB patients (group 3)

17. D.C. 50, w  RA§  500 0 0 0 1:512, neg.  87, 82, 75, 66, 58, 55, 47, 41, 39, 37, 30, 23, 21, 18
18. G.S. 33, m  Neuritis§  8,000 4,500 8,000 3,000 1:128, neg.  87, 82, 75, 58, 56, 55, 41, 40, 30, 29, 21, 14
19. H.W. 58, m  M. Reiter  12,000 4,500 1,600 100 1:256, neg.  87, 82, 75, 66, 60, 58, 56, 55, 47, 44, 41, 40, 39, 37, 30, 29, 23, 21
20. I.K. 31, f  Oligoarthritis§  32,500 13,000 8,000 20,000 neg., neg.  neg.


Antibodies. Sera tested in the IFA were preabsorbed with T. phagedenis to increase the specificity of the test (4, 10, 11). Theoretically, this procedure may have lowered antibody titers in general since cross-reactive epitopes may be the major antigenic sites. Therefore, Western blot analysis was performed without preabsorption. Comparing both tests, only two sera were identified that were negative in the IFA and positive in the immunoblot. These sera were additionally analyzed in the IFA without preabsorption with T. phagedenis, again yielding negative results. With regard to Western blot analysis, there remains the possibility that low concentrations of specific antibodies, especially those directed against OspA, were diluted out by dilution steps necessary to perform immunoblots. However, recently a series of LB sera was tested by our group in a self-developed ELISA using recombinant OspA and flagellin as antigens. In these experiments, similar frequencies of specific antibodies were detected compared with the Western blot in this study (Kramer, M., et al., unpublished data). Furthermore, it is unlikely that strain-specific differences of the OspA protein may account for the inability to detect specific antibodies since the OspA appears to be highly conserved even among isolates from two different continents (15). Thus, the apparent dissociation between T and B cell responses, initially described by Dattwyler et al. (5) and now confirmed by us using recombinant spirochetal antigens, remains to be explored. Possibly, the B. burgdorferi–specific T cells as revealed by in vitro restimulation are in a resting stage in vivo and are not able to provide sufficient signals for B cells to produce antibodies, in particular to OspA. This may in part be due to early antibiotic therapy as described previously (5, 7). In fact, in our study all five seronegative patients with late LB had been treated with antibiotics. Therefore, the inability to detect anti–spirochetal antibodies in the serum may be due to a refractory stage of the respective T cells rather than to the absence of previously activated B cells.

The situation of divergence of cellular and humoral responses is even more complicated by the fact that in one of the four individuals with detectable antibodies to OspA there was no T cell response to the same antigen. Clearly, further studies
are required to gain more insight into the activation of T cells and B cells in LB.

Analysis of cellular responses in the control groups revealed that T cell reactivity to OspA was not restricted to LB patients but was also detectable in healthy donors and in patients with other inflammatory diseases. In HD there was a highly significant correlation between T cell responses to OspA and to T. phagedenis. These results suggest that other saprophytic spirochetes share T cell epitopes with OspA from B. burgdorferi. This assumption is supported by recent observations by Magarelli et al. (24) and Cooke et al. (34) demonstrating antibody cell cross-reactivity between B. burgdorferi and Treponema, i.e., Treponema denticola. The latter agent is a saprophyte of the human oral mucosa and is frequently found in periodontitis. It may therefore also trigger cellular cross-reactions.

However, despite these possible cross-reactions, it was clearly evident that the T cell reactivity to whole B. burgdorferi and to OspA was significantly elevated in patients with LB. Although OspA and flagellin may not be the ideal antigens to unequivocally link the respective proliferative responses to B. burgdorferi, our findings suggest that in the future a panel of standardized recombinant proteins may function as surrogates for whole B. burgdorferi. Taken together, the analysis of the T cell reactivity will not only provide significant insights into the pathogenic disease mechanisms but, especially in view of the complexity of the humoral and the cellular immune responses, also appears to be an important tool for the diagnosis of LB.

Acknowledgments

We thank Dr. R. Winchester, Columbia University, New York, for helpful discussions and thoroughly reviewing the manuscript. This study was supported in part by the Federal Ministry for Research and Technology (grant 01 KI 9001). Andreas Krause is a post-doctoral fellow of the Deutsche Forschungsgemeinschaft (grant Kr 997/1-2).

References